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Abstract. – OBJECTIVE: Obesity plays a rele-
vant pathophysiological role in the development 
of health problems, arising as result of complex 
interaction of genetic, nutritional and metabol-
ic factors. We conducted a dietary intervention 
case-control randomized trial, to compare the 
effectiveness on body composition of two nutri-
tional protocols: a very-low-carbohydrate keto-
genic diet (VLCKD), integrated by an aminoacid 
supplement with whey protein, and very low re-
stricted-calorie diet (VLCD).
PATIENTS AND METHODS: The clinical study 
was conducted with a randomized case-con-
trol in which twenty-five healthy subjects gave 
informed consent to participate in the interven-
tional study and were evaluated for their health 
and nutritional status, by anthropometric, and 
body composition evaluation. 
RESULTS: The results of this pilot study show 
that a diet low in carbohydrates, associated with 
a decreased caloric intake, is effective in weight 
loss. After VLCKD, versus VLCD, no significant 
differences in body lean of the trunk, body lean 
distribution (android and gynoid), total body 
lean were observed (p > 0.05). After VLCKD, no 
increasing of sarcopenia frequency, according 
ASSMI, was observed.
DISCUSSION: Many studies have shown the 
effectiveness of the ketogenic diet on weight 
loss; even if not know how to work effectively, as 
some researchers believe that the weight loss is 
due to reduced calorie intake, satiety could also 
be induced by the effect of the proteins, rather 
than the low-carbohydrates.
CONCLUSIONS: Our pilot study showed that 
a VLCKD was highly effective in terms of body 
weight reduction without to induce lean body 
mass loss, preventing the risk of sarcopenia. 
Further clinical trials are needed on a larger pop-
ulation and long-term body weight maintenance 
and risk factors management effects of VLCKD. 
There is no doubt, however, that a proper dietary 
approach would impact significantly on the re-
duction of public expenditure costs, in view of 
prospective data on increasing the percentage 
of obese people in our nation.
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Introduction
Obesity is defined by the World Health 
Organization (WHO) as “a condition in which 
percentage body fat (PBF) is increased to an ex-
tent in which health and well-being are impaired”. 
Due to the alarming incidence and prevalence in-
crease, it has been declared as a “global epidem-
ic”1. Obesity can be considered mainly as a mul-
tifactorial disease dependent on environmental 
factors, such as diet and poor physical activity, 
genetic and metabolic factors2. 
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A cross-talk between skeletal muscle and 
adipose tissue has been proposed and linked 
with the control of body weight, both fat stores 
and muscle mass. Sarcopenia has profound 
physiologic and clinical consequences, includ-
ing but not limited to impaired protein turn-
over, mobility loss, osteoporosis, increased 
fracture risk, dyslipidemia, insulin resistance, 
overall frailty, and increased mortality. The 
combination of sarcopenia and obesity, de-
fined as sarcopenic obesity, is an important 
public health problem that induces fragility in 
the elderly, and it is associated with functional 
limitations and increased mortality3,4. 
The effects of diet on metabolic pathways re-
lated diabetes, cardiovascular diseases, and other 
chronic non-communicable diseases (CNCD) is 
currently under investigation. 
Obesity, cardiovascular diseases, diabetes 
mellitus, chronic kidney disease, osteoporo-
sis, sarcopenia, Alzheimer’s disease, and many 
cancers can be grouped as non-transmissible 
CNCD.
A therapeutic life style changes for health sta-
tus and wellbeing, that included dietary habitus 
and physical activity, represent an important ap-
proach to prevent and treat the metabolic imbal-
ance.
According to the position of the Academy of 
Nutrition and Dietetics, the successful treatment 
of obesity requires adoption and maintenance of 
therapeutic life style changes, in terms of dietary 
intake and physical activity5.
The primary determinant of weight loss is en-
ergy deficit. The physician with a patient in the 
condition of insulin resistance, metabolic inflex-
ibility and inflammation, must be able to choose 
between several options of diet therapy. 
The best diet for losing weight and maintain-
ing good health is the Mediterranean diet6,7. 
However, in the strategy of weight loss there are 
several dietary approaches available, divided be-
tween low calories diet (LCD, 800 kcal day-1) 
and very low-calorie diets (VLCDs, < 800 kcal 
day-1)8. Moreover, the choice of the physician 
should be based on the effectiveness of the loss 
of fat mass and the patient safety during dietary 
intervention.
VLCDs are generally used as part of a compre-
hensive intervention that includes medical mon-
itoring and a program of lifestyle modification, 
and they are considered safe and effective when 
used by appropriately selected individuals under 
careful medical supervision9.
As it is important to preserve lean body mass, 
VLCD is based on 70 to 100 g/day of protein or 
0.8 to 1.5 g protein/kg of ideal body weight10.
Moreover, VLCDs includes the very-low-car-
bohydrate diet (VLCKD) can lead to a state of ke-
tosis, in which the concentration of blood ketones 
(acetoacetate, 3-β-hydroxybutyrate, and acetone) 
increases due to increased fatty acid breakdown 
and activity of ketogenic enzymes.
It has been demonstrated that a very low-cal-
orie ketogenic diet (VLCKD) was more effec-
tive than Mediterranean Diet in significantly 
decreasing carbon dioxide body stores, which 
may theoretically be beneficial for patients with 
increased carbon dioxide arterial partial pres-
sure due to respiratory insufficiency or fail-
ure10. However, VLCDs are considered to be 
appropriate only for those patients with a body 
mass index11 (BMI) >30 kg/h2, that are at risk 
of cardio-metabolic diseases, needing a sudden 
weight loss. As the adipose tissue and skeletal 
muscle have a role in lipid and glucose me-
tabolism, due to the large number of bioactive 
proteins, secreted by those tissue and related 
to some cardiovascular risk factors, limitation 
would be based only on weight and BMI, with-
out taking into account the body composition, 
in terms of ratio between body fat and body 
lean, because it is an increase in morbidity and 
mortality related to the percentage of adiposi-
ty12. Since it is possible to identify obese sub-
jects based on the amount of fat mass also in 
the classes of normal and overweight according 
to the BMI13, it seems important to use the per-
centage of body fat (PBF) for the diagnosis of 
obesity, and to choose a personalized dietary 
intervention with the aim of reducing total fat 
body mass (TBFat), while preserving lean body 
mass (TBLean).
As the role of VLCKD in the lean body mass 
preservation is not well established, we conduct-
ed a dietary intervention case-control randomized 
trial, to compare the effectiveness on body com-
position of two nutritional protocols: a VLCKD, 
in which 50% of protein intake is integrated by an 
aminoacid supplement, and VLCD. 
We have assumed that VLCKD can better pre-
serve lean body mass during weight loss, saving 
from diet-induced sarcopenia.
Given the clinical significance of sarcopenia 
and obesity, as well as their close relationship in 
terms of body composition, we comprehensively 
analyzed TBFat, TBLean, and anthropometric 
parameters in obese patients after weight loss. 




The clinical study was conducted with a ran-
domized case-control design between October 
2015 to November 2015. 
The study started at T0 with the enrollment of 
thirty obese subjects, consecutively recruited with-
in a program of routine medical check-up at the 
Section of Clinical Nutrition and Nutrigenomic, 
at the University of Rome “Tor Vergata”, and at 
“Nuova Annunziatella” Clinic, Rome, Italy.
Twenty-five healthy subjects gave informed 
consent to participate in the interventional study, 
which was performed. All the subjects were eval-
uated for their health and nutritional status, by an-
thropometric, and body composition evaluation. 
Subjects eligible for the study met the follow-
ing inclusion criteria: age between 18 and 65 
years, with a BMI ≥ 25 kg/m2, percentage of body 
fat (PBF) ≥ 25 for male, and ≥ 30 for female.
Exclusion criteria were as follows: pregnancy, 
breast-feeding, type 1 diabetes, heart failure, en-
docrine disorders, liver, kidney, autoimmune, vi-
ral chronic (hepatitis C, B, HIV), and neoplastic 
disease; serum creatinine level of 2 mg per decili-
ter (177 μmol per liter) or more, liver dysfunction 
(an increase by a factor of at least 2 above the up-
per limit of normal in GOT and GPT), cortico-
steroid and chronic inflammatory therapy; partic-
ipating in another diet trial.
Subjects, who were eligible for the study, were 
randomly (R) divided into two groups (X and Y).
The group X received the VLCKD, and the 
group Y received the VLCD. 
The study was conducted in double-blind.
It was asked to the subjects not to change their 
lifestyle habits. Any adverse effect has been prop-
erly signed.
The participants received no financial compen-
sation or gifts. Each participant provided written 
informed consent.
Analysis were performed at the Section of 
Clinical Nutrition and Nutrigenomic, Department 
of Biomedicine and Prevention of the University 
of Rome “Tor Vergata”. 
Anthropometric Measurements
At T1, after a 12-hour overnight fast, all subjects un-
derwent anthropometric evaluation. Anthropometric 
measurements for all participants according to stan-
dard method were carried out14. All the individuals 
were instructed to take off their clothes and shoes be-
fore undergoing the measurements. 
Waist and hip circumferences were taken us-
ing a flexible steel metric tape to the nearest 0.5 
cm. Hip circumference was measured according 
to International Society for the Advancement of 
Kin anthropometry protocol taken at the greatest 
posterior protuberance of the buttocks. Waist 
circumference was measured just above the iliac 
crest as recommended in the National Institute 
of Health Guidelines Body weight (kg)15 was 
measured to the nearest 0.1 kg, using a balance 
scale (Invernizzi, Rome, Italy). Height (m) was 
measured using a stadiometer to the nearest 0.1 
cm (Invernizzi, Rome, Italy). BMI was calcu-
lated using the formula: BMI = body weight /
height2 (kg/m2).
Dual X-ray Absorptiometry (DXA)
To assess body composition analysis, that gives 
the possibility to measure total body fat (TBFat) 
and total body lean (TBLean), DXA (i-DXA, GE 
Medical Systems, Milwaukee, WI, USA) evalua-
tion was performed at baseline16.
The technique combined a total body scanner, 
an X-ray source, an internal wheel to calibrate 
the bone mineral compartment, and an external 
lucite/aluminum phantom to calibrate soft mass. 
Calibration and verification of the reproducibili-
ty of the data were daily performed. The subjects 
have received instructions before attending to the 
medical views. Individuals were asked to remove 
all clothing except for undergarments including 
shoes, socks and metal items prior to begin DXA 
examination in the supine position, with the scan 
from the head and moving in a rectilinear pattern 
down the body to the feet. The average measure-
ment time was 20 min. The effective radiation 
dose from this procedure is about 0.01 mSv. The 
coefficient of variation (coefficient of variation = 
100 x SD/mean) intra and inter subjects ranged 
from 1% to 5%. The coefficient of variation for 
bone measurements is less than 1%; coefficient 
of variation on this instrument for five subjects 
scanned six times over a nine months period were 
2.2% for total body fat (TBFat), and 1.1% for total 
body lean (TBLean).
Total body fat percentage (PBF) was calculated 
as TBFat mass divided by total mass of all tissues, 
considering also the total body bone (TBBone), as 
the follow: PBF = (TBFat + TBLean + TBBone) 
x 100.
Appendicular Skeletal Muscle Mass Index 
(ASMMI) = (Legs Muscle Mass (kg) + Arms 
Muscle Mass (kg)/Height (m2) (Men < 7.59 kg/
m2, Women < 5.47 kg/m2).
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Dietary Treatment 
The very-low-carbohydrate ketogenic diet 
(VLCKD) aimed at an energy intake of 450-500 
kcal per day for female and 650-700 kcal per day 
for male, with 35-40% of calories from fat, < 
10% of calories from saturated fat, 5% of calo-
ries from carbohydrates (< 6 g), and 55-60% of 
calories from protein, corresponding to 1.2 g (fe-
male) or 1.5 g (male) / kg of body weight, and an 
intake of 25 mg of fiber per day. The half of the 
amount of daily protein was reached using amino-
acid supplement, called Amin 21K (Italfarmacia, 
Rome, Italy). The correct administration of diet 
was evaluated by urinary keto-stick. The powder 
of aminoacid was dissolved in water and drunk at 
the breakfast and lunch or dinner.
The very low restricted-calorie diet (VLCD) 
aimed at an energy intake of 450-500 kcal per 
day for female and 650-700 kcal per day for male, 
with 35-40% of calories from fat, < 10% of calo-
ries from saturated fat, 15-20% of calories from 
carbohydrates (< 20 g (female) or < 30 g (male), 
and 45-50% of calories from protein, correspond-
ing to 0.9 g (female) or 1.1 g (male) / kg of body 
weight, and an intake of 25 mg of fiber per day.
In all cases, a capsule of multivitamin, prop-
er integration of mineral salts and an alkalizing 
product were prescribed. The correct administra-
tion of diet was evaluated by urinary keto-stick.
Statistical Analysis
A paired t-test or a non-parametric Wilcoxon 
test were performed to evaluate differences at 
baseline and after nutritional intervention. 
The differences between parameter at baseline 
and after diet were calculated as the follow: Δ% 
= [(Z-W)/W] x100, where Δ% is the percentage 
variation of each parameter, calculated as ratio of 
absolute variation to the base value.
In all statistical tests performed, the null hy-
pothesis (no effect) was rejected at the 0.05 level 
of probability. 
Results
Of the 25 subjects enrolled, four of them did 
not meet the inclusion criteria; therefore, 21 
participants were resulted eligible for the study. 
Three subjects declined to participate after one 
week, so eighteen patients completed the study, 
with a mean age of 47.54 ± 14.38 years. The mean 
age of X group was 45.40 ± 16.39, of the Y group 
was 49.33 ± 13.78 (p = 0.68). The population was 
represented by the 72.72% of female and 27.28% 
of male.
At baseline (T0), the mean of BMI was 33.69 
± 3.51 kg/m2. According to BMI, the 54.54% of 
the population was overweight, the 45.46% was 
obese. In the X group the 80% was obese. In the 
Y group the 16.67% was obese.
All the subjects were obese according to PBF 
estimated by DXA (> 30% for female, > 25% for 
male).
The characteristics of the participants at base-
line (T0) after 3 weeks of each dietary treatment 
(T1) are shown in Table I (VLCKD) and Table II 
(VLCD).
  Baseline (T0) After 3 weeks of VLKD (T1)
 n = 9 mdia (SD) media (SD) p
Weight (kg)a 99.78 (4.57) 92.80 (4.78) 0.00*
BMI (kg/m2)a 33.69 (3.51) 31.36 (3.59) 0.00*
Waist circumference (cm)a 103.90 (5.98) 98.40 (5.91) 0.00*
Abdomen circumference (cm)a 111.82 (5.42) 108.20 (6.73) 0.03*
hip circumference (cm)a 114.30 (6.42) 111.30 (7.73) 0.01*
Trunk Body Fat (kg)a 20.37 (5.59) 19.78 (4.99) 0.59
Trunk Body Lean (kg)a 25.06 (5.55) 26.23 (4.74) 0.69
Android Body Fat (kg)a 3.3046 (1.11) 3.2078 (0.92) 0.76
Android Body Lean (kg)a 3.75 (1.09) 3.92 (0.61) 0.75
Gynoid Body Fat (kg)a 6.01 (1.50) 5.70 (1.10) 0.30
Gynoid Body Lean (kg)a 8.06 (2.18) 8.59 (1.81) 0.67
Total Body Fat (kg)a 37,24 (9.31) 34.79 (9.38) 0.02*
Total Body Lean (kg)a 53.01 (12.86) 54.93 (8.96) 0.75
Percentage Body Fat (%)a 40.30 (8.25) 37.52 (9.63) 0.30
Table I. Comparison between the body composition before and after administration of very-low-carbohydrate ketogenic diet 
for 3 weeks.
Paired t-test a or a non-parametric Wilcoxon testb.
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After 3 weeks of diet (T1), according to BMI, 
the 72.72% of the population was overweight, the 
27.28% was obese. In the X group the 60% was 
obese. In the Y group, no subject was classified 
as obese.
All groups had a significant decreased in BMI: 
after VLCKD the Δ% of BMI was = -6.91, (p = 
0.00), and after VLCD the Δ% of BMI was = -7.91 
(p = 0.00). 
Both groups lost weight, but the reduction was 
greater in the VLCD (Δ% = -7.98; p = 0.00) com-
pared to VLCKD (Δ% = -6.99; p = 0.00). 
However, in both groups no significant reduc-
tion of PBF was observed (p >0.05).
After VLCKD, no significant differences in 
body fat of the trunk, body fat distribution (an-
droid and gynoid) were observed, whereas, ab-
domen circumference (Δ% = -3.23), hip circum-
ference (Δ% = -7.98), waist circumference (Δ% = 
-5.29), and total body fat (Δ% = -6.57) were sig-
nificantly different (p < 0.05). 
After VLCD, no significant differences in waist 
circumference, body fat of the trunk were ob-
served. However, abdomen circumference (Δ% = 
-3.25), hip circumference (Δ% = -3.14), android 
body fat (Δ% = -13.40) and gynoid body fat distri-
bution (Δ% = -19.22), total body fat (Δ% = -7.47) 
were significantly different (p < 0.05). 
Moreover, after VLCD a significant decrease of 
total body lean of the trunk (Δ% = -7.31), android 
lean body distribution (Δ% = -11.85), gynoid lean 
body distribution (Δ% = -5.47), and total body 
lean (Δ% = -8.46) were highlighted (p < 0.05). 
After VLCKD, no significant differences in body 
lean of the trunk, body lean distribution (android 
and gynoid), total body lean were observed (p > 
0.05). 
Moreover, the frequency of sarcopenia at base-
line according to ASMMI was 20% in the X 
group; after VLCKD, no sarcopenic subject was 
highlighted.
Discussion 
Many research have shown the effectiveness 
of the ketogenic diet on weight loss17; even if not 
know how to work effectively, as some research-
ers believe that the weight loss is due to reduced 
calorie intake, satiety could also be induced by 
the effect of the proteins, rather than the low-car-
bohydrates20. Others, however, believe that in 
fact there is a metabolic gain, based on the first 
law of hemodynamics or law of conservation of 
energy11. However, other authors still have re-
marked old considerations for which little would 
be important macronutrients present in the di-
et, only effective for the reduction of calories22. 
Contrary to these opinions, the majority of stud-
ies has shown that people who follow a diet low 
in carbohydrates lose more weight in the first 3-6 
months compared to those who follow balanced 
diets23-25, perhaps because the proteins of the 
ketogenic diet represent a wasteful process for 
the human body which allows a greater weight 
loss21,26,27. The energy cost of gluconeogenesis 
has been confirmed18,20 and it has been calculat-
ed at ∼400-600 Kcal/day (due to both endoge-
  Baseline (T0) After 3 weeks of VLKD (T1)
 n = 9 mdia (SD) media (SD) p
Weight (kg)a 74.77 (5.04) 68.80 (4.24) 0.00*
BMI (kg/m2)a 29.21 (1.07) 26.90 (1.34) 0.00
Waist circumference (cm)b 84.72 (2.73) 83.75 (7.05) 0.34
Abdomen circumference (cm)a 99.92 (3.18) 96.67 (3.34) 0.02*
Hip circumference (cm)a 109.42 (3.61) 105.98 (2.61) 0.00*
Trunk Body Fat (kg)b 16.20 (1.86) 15.32 (2.11) 0.1
Trunk Body Lean (kg)b 18.32 (1.09) 16.98 (1.25) 0.03*
Android Body Fat (kg)a 2.76 (0.41) 2.39 (0.45) 0.00*
Android Body Lean (kg)a 2.70 (0.21) 2.38 (0.20) 0.00
Gynoid Body Fat (kg)b 6.71 (2.05) 5.42 (0.64) 0.03*
Gynoid Body Lean (kg)a 5.85 (0.57) 5.53 (0.46) 0.04*
Total Body Fat (kg)a 33.06 (3.60) 30.59 (3.65) 0.00*
Total Body Lean (kg)a 39.00 (3.03) 35.70 (3.09) 0.00*
Percentage Body Fat (%)a 44.37 (3.35) 44.53 (4.14) 0.74
Table II. Comparison between the body composition before and after administration of  very low restricted-calorie diet  for 3 
weeks.
Paired t-test a or a non-parametric Wilcoxon testb.
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nous and food source proteins26. Except this, no 
experimental evidences support this hypothesis, 
on the contrary, a recent work has shown that 
there are no changes in energy expenditure af-
ter a VLCKD28. Certainly the effects of the loss 
of weight of the VLCD depend on various fac-
tors: decreased appetite for satiety provided pro-
tein20,30, effects on appetite control hormones29 
and to a possible direct appetite-suppressant ac-
tion of the KBs21; reduction in lipogenesis and 
increased lipolysis18,19; reduction in the resting 
respiratory quotient and, therefore, greater meta-
bolic efficiency in consuming fats28,32; increased 
metabolic costs of gluconeogenesis and the ther-
mic effect of proteins21,26.
There are several evidence support about using 
of whey protein to increase anabolic hormones, 
like insulin and GH. However, whey protein has 
potential as a functional food component to con-
tribute to the regulation of body weight by pro-
viding satiety signals27. Whey protein appears 
to have a blood glucose lowering effect partly 
mediated by incretins. Effects of whey protein 
on metabolic mechanism seem be in muscle pro-
tein synthesis18. Several results in different stud-
ies proved the importance of protein quality as a 
determinant of lean body mass responses during 
resistance training44. So we supposed, during 
weight lost, biological value of protein is consti-
tutive. In contrast, there are no clear-cut effects 
shown on blood lipids and lipoproteins, blood 
pressure and vascular function.
The results of this pilot study show that a 
diet low in carbohydrates, associated with a 
decreased caloric intake, is effective in weight 
loss. Although compliance with the diets was 
assessed primarily by dietary records, these da-
ta are supported by more objective measures. 
Thus, we believe that the outcomes of this study 
can be attributed primarily to differences in the 
prescribed diets of the two groups and are ap-
plicable to the large number of obese. Also, the 
amount of body water plays an important role 
as the weight loss may be due to diuresis conse-
quent to caloric restriction or reduction of body 
water followed presumably by the reduction of 
glycogen stores33,34. However, these studies were 
of very short duration, from 2-3 weeks in length. 
Most diets that have a significant restriction of 
calories cause a sodium diuresis that occurs over 
the first week or 3 of their use, and in fact, we 
noted the most rapid weight loss in both groups 
over this period. Our body composition analysis 
revealed a similar percentage of body fat as in 
low-fat diet group. Because we think it is far-
fetched to think that the change of weight in the 
groups at 3 and 6 months is due to the variation 
in body water in the diet low in carbohydrates, 
but the reduction of caloric consumption35. 
Although the inaccuracy of dietary records for 
obese individuals is well documented36,37, not 
easy to think that reducing the weight in the two 
groups is only due to a different calorie intake 
but probably also to a different exercise. Not 
very clear, moreover, it appeared to be the re-
duction of food intake in the group of patients 
in a diet low in carbohydrates to a level equal 
to VKLCD group were following a prescribed 
restriction of calories. This suggests the possi-
bility that the diet low in carbohydrates gives 
a greater sense of satiety. Several reports have 
suggested, in fact, that the protein satisfies the 
appetite more than carbohydrates and fats38,39. 
Although it is known as ketosis secondary to 
increased protein intake results in reduced ap-
petite, this does not seem likely based on our 
data. At the end of this paper it is important to 
emphasize certain points. First, a single study 
cannot define criteria for safety and effective-
ness, also because our results are still limited 
by the lack of durability, but with the certain-
ty that a diet low in carbohydrates will produce 
weight loss and reduction of cardiovascular risk 
factors and cancer in analysis periods longer41. 
Care must be taken, for the low intake of calci-
um and fiber in the diet with reduced carbohy-
drate content and the fact that ketosis has been 
shown to be related to myocardial dysfunction 
in children42. Finally, the observed preservation 
of muscle mass brought about during a VKLCD 
is possible at least four possible mechanisms43. 
May be involved as the surge of low levels of 
blood sugar are a stimulus for its secretion and 
it could be that the protein mass of skeletal mus-
cle affected by adrenergic influences. The liver 
produces ketone bodies during a VKLCD and 
they flow from the liver to extra-hepatic tissues 
(e.g., brain, muscle) for use as a fuel. As low 
blood sugar increases GH secretions, one could 
speculate that a VKLCD increases GH levels. 
A VKLCD is almost always relatively high in 
protein and there is evidence that high protein 
intake increases protein synthesis by increas-
ing systemic amino acid availability44, which 
is a potent stimulus of muscle protein synthe-
sis45. During weight loss, higher protein intake 
reduces loss of muscle mass and increases loss 
of body fat46. Can interact with the insulin to 
Ketogenic Diet to preserve muscle mass
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regulate the control of protein synthesis to sup-
port the muscle mass during periods of reduced 
caloric intake47.
Our pilot double-blind study showed that a 
VLCKD was highly effective in terms of body 
weight reduction without to induce lean body 
mass loss, preventing the risk of sarcopenia. 
Together these data, serve as clinical information 
to support measure and diet selection for preven-
tion of risks induced during dietary treatment in 
obesity management. 
Further clinical trials are needed on a larger pop-
ulation and long-term body weight maintenance 
and risk factors management effects of VLCKD. 
As the full spectrum of metabolic effects induced 
by VLCKD is not completely characterized, new 
trials that are specifically designed to assess the 
combined effects of genotypes and dietary inter-
vention are needed. Nutrigenomic, nutrigenetic 
and biochemical analysis could be performed to 
ensure safety during the dietary treatments, before 
definitive conclusions can be made48. 
The prospect of personalized medicine may help 
move obesity prevention and treatment from univer-
sal to precision approaches, towards weight-loss pro-
grams tailored to a person’s genome49. The advance 
in helping obese people to achieve a healthier weight 
will be the use of behavior, body composition and ge-
netic data to customize diets as an approach known 
as “precision weight loss”.
Public health expenditure in Italy in 2010 
amounted to 113.5 billion euro, or 7.3% of 
GDP50,51. The projection of public health expen-
diture in 2050 has focused on estimating the im-
pact of demographic and economic components. 
Demographic changes and the growth of dispos-
able income impact to over 168 billion euro on the 
accounts of health than in 201050,51. At the end of 
this period, the public health expenditure would 
amount to a value close to 281.5 billion euro, 
equal to 9.7% of GDP. This model is based on the 
assumption of a constant current epidemiological 
picture. It can, however, be assumed in the fore-
cast model to introduce a change in the epidemio-
logical picture associated to the increase of a risk 
factor of many diseases (cardiovascular disease, 
diabetes, some cancers, etc.) such as obesity. The 
basic assumptions are the following: italian obese 
children are 11% of the population; it is estimated 
that the number of obese adults will increase by 
2.4% annually until 2025, and by 2.8% annually 
from 2025 to 2050, taking into account that 70% 
of obese children remain obese as an adult now, 
and that on average one third of obese adults had 
been obese since childhood; it assumes that the 
health care cost of an adult obese person is on 
average 1400 euro more than the average health 
cost per capita. Crossing the figures for per capita 
health care costs associated with each obese and 
the growing number of obese, you can estimate 
the greatest impact on health care costs. With a 
forecast for 2050, this simulation leads to more 
spending, compared to the base case of the model, 
for about 24.3 billion euro, resulting in a ratio of 
health expenditure to GDP of around 10.6% (com-
pared with 9.7% of the base case of the forecasting 
model). The total cost caused the epidemiologi-
cal picture simulated for the 2010-2050 period is 
347.5 billion Euros for the diseases to which effect 
is subject more frequently than a person of normal 
weight. Changing the obesity epidemiological 
assumptions combined with those on the demo-
graphic mix brings the number of obese nearly 14 
million in 2050 (compared to assumptions) about 
5 million that would occur in the event that were 
modified. So an increase of 1400 Euros more per 
year for obesity-related diseases for 20 years of 
survival would produce 28,000 euro per capita in 
more spending. If these represent 10% of the adult 
population over 18 years (10% of 50 million peo-
ple = 5 million people on average) would lead to a 
higher total expenditure of EUR 140 billion in 20 
years, i.e. 7 billion more (or less if you are cured), 
in practice roughly a 5-6% spending more than 
the estimates if they are not cared for.
Conclusions
The prospect of personalized medicine may 
help move obesity prevention and treatment 
from universal to precision approaches, towards 
weight-loss programs tailored to a person’s ge-
nome49. The advance in helping obese people to 
achieve a healthier weight will be the use of be-
havior, body composition and genetic data to cus-
tomize diets as an approach known as “precision 
weight loss”.
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